The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice
- PMID: 24050894
- DOI: 10.1016/j.juro.2013.09.020
The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice
Abstract
Purpose: Activators of soluble guanylyl cyclase are of potential interest as treatment for cardiovascular diseases but to our knowledge they have never been proposed to treat overactive bladder. We evaluated the effects of the soluble guanylyl cyclase activator BAY 60-2270 on voiding dysfunction and detrusor overactivity in a mouse model of obesity associated overactive bladder.
Materials and methods: C57BL/6 male mice fed for 10 weeks with standard chow or a high fat diet were treated with 1 mg/kg BAY 60-2770 per day for 2 weeks via gavage. Cystometric evaluations were done and responses to contractile agents in isolated bladders were determined.
Results: Obese mice showed an irregular micturition pattern characterized by significant increases in voiding and nonvoiding contractions, which were normalized by BAY 60-2770. Carbachol, KCl and CaCl2 produced concentration dependent contractions in isolated bladder strips, which were markedly greater in obese than in lean mice. BAY 60-2770 normalized bladder contractions in the obese group. A 78% increase in reactive oxygen species generation in the bladder tissue of obese mice was observed, which was unaffected by BAY 60-2770. Treatment with BAY 60-2770 generated a tenfold increase in cyclic guanosine monophosphate in the bladders of obese mice without affecting the nucleotide level in the lean group. Protein expression of the soluble guanylyl cyclase α1 and β1 subunits was decreased 40% in the bladder tissue of obese mice but restored by BAY 60-2770.
Conclusions: Two-week BAY 60-2770 therapy increased cyclic guanosine monophosphate and rescued expression of the soluble guanylyl cyclase α1 and β1 subunits in bladder tissue, resulting in great amelioration of bladder dysfunction.
Keywords: LDL; NO; NVC; OAB; ROS; cGMP; cyclic guanosine monophosphate; low density lipoprotein; lower urinary tract symptoms; nitric oxide; nonvoiding contraction; obesity; overactive; overactive bladder; reactive oxygen species; sGC; soluble guanylate cyclase; soluble guanylyl cyclase; urinary bladder.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.J Pharmacol Exp Ther. 2014 Apr;349(1):2-9. doi: 10.1124/jpet.113.211029. Epub 2014 Jan 13. J Pharmacol Exp Ther. 2014. PMID: 24421320
-
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.Neurourol Urodyn. 2015 Nov;34(8):787-93. doi: 10.1002/nau.22665. Epub 2014 Sep 17. Neurourol Urodyn. 2015. PMID: 25230878
-
Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.J Sex Med. 2014 Nov;11(11):2661-70. doi: 10.1111/jsm.12682. Epub 2014 Sep 5. J Sex Med. 2014. PMID: 25196910
-
Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.Curr Opin Investig Drugs. 2005 Sep;6(9):874-8. Curr Opin Investig Drugs. 2005. PMID: 16187686 Review.
-
Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.Clin Chem Lab Med. 2003 Jul;41(7):865-70. doi: 10.1515/CCLM.2003.131. Clin Chem Lab Med. 2003. PMID: 12940510 Review.
Cited by
-
Effects of different diets used to induce obesity/metabolic syndrome on bladder function in rats.Am J Physiol Regul Integr Comp Physiol. 2023 Jan 1;324(1):R70-R81. doi: 10.1152/ajpregu.00218.2022. Epub 2022 Nov 14. Am J Physiol Regul Integr Comp Physiol. 2023. PMID: 36374176 Free PMC article.
-
Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.Naunyn Schmiedebergs Arch Pharmacol. 2022 Aug;395(8):887-906. doi: 10.1007/s00210-022-02249-9. Epub 2022 May 12. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35545721 Free PMC article. Review.
-
Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants.Int J Mol Sci. 2021 Jun 2;22(11):6014. doi: 10.3390/ijms22116014. Int J Mol Sci. 2021. PMID: 34199527 Free PMC article. Review.
-
Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains.Molecules. 2018 Aug 25;23(9):2141. doi: 10.3390/molecules23092141. Molecules. 2018. PMID: 30149624 Free PMC article.
-
Activation of PKG and Akt Is Required for Cardioprotection by Ramelteon-Induced Preconditioning and Is Located Upstream of mKCa-Channels.Int J Mol Sci. 2020 Apr 8;21(7):2585. doi: 10.3390/ijms21072585. Int J Mol Sci. 2020. PMID: 32276406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical